IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
IMUNON (NASDAQ: IMNN) reported third quarter 2025 results and clinical progress on November 13, 2025. The company highlighted a median 13-month overall survival (OS) benefit observed with IMNN-001 in OVATION 2 and translational data showing tumor microenvironment shifts (CD8+ increases, reduced IDO/PD-L1/Treg) in 50-80% and 65-80% of paired samples. IMUNON described expanded Phase 3 OVATION 3 enrollment and an adaptive, event-driven trial design aligned with FDA precedents.
Financially, Q3 net loss was $3.4M (vs $4.8M prior year), operating expenses fell ~30%, and cash was $5.3M, which the company says funds operations into Q1 2026 while it pursues selective financing.
IMUNON (NASDAQ: IMNN) ha riportato i risultati del terzo trimestre 2025 e i progressi clinici il 13 novembre 2025. L'azienda ha evidenziato un beneficio mediano di 13 mesi di sopravvivenza globale (OS) osservato con IMNN-001 in OVATION 2 e dati traslazionali che mostrano spostamenti nel microambiente tumorale (aumento di CD8+, riduzione di IDO/PD-L1/Treg) nel 50-80% e nel 65-80% dei campioni accoppiati. IMUNON ha descritto l'espansione dell'iscrizione nello studio di fase 3 OVATION 3 e un disegno di studio adattivo, guidato da eventi, in linea con i precedenti della FDA.
Finanziariamente, la perdita netta del Q3 è stata di $3.4M (rispetto a $4.8M dell'anno precedente), le spese operative sono diminute di circa 30%, e la cassa era di $5.3M, che l'azienda afferma finanzia le operazioni fino al primo trimestre 2026 mentre persegue finanziamenti selettivi.
IMUNON (NASDAQ: IMNN) informó los resultados del tercer trimestre de 2025 y avances clínicos el 13 de noviembre de 2025. La compañía destacó un beneficio mediano de supervivencia global (OS) de 13 meses observado con IMNN-001 en OVATION 2 y datos traslacionales que muestran cambios en el microentorno tumoral (aumento de CD8+, reducción de IDO/PD-L1/Treg) en el 50-80% y el 65-80% de las muestras pareadas. IMUNON describió la expansión de la inscripción en la fase 3 OVATION 3 y un diseño de ensayo adaptativo, impulsado por eventos, alineado con precedentes de la FDA.
Financieramente, la pérdida neta del Q3 fue de $3.4M (frente a $4.8M el año anterior), los gastos operativos cayeron aproximadamente un 30%, y el efectivo fue de $5.3M, lo que la empresa dice que financia las operaciones hasta el primer trimestre de 2026 mientras busca financiamiento selectivo.
IMUNON (NASDAQ: IMNN)은 2025년 3분기 실적과 임상 진행 상황을 2025년 11월 13일 발표했다. 회사는 OVATION 2에서 IMNN-001로 관찰된 중간값 13개월의 전체생존(OS) 이익과 50-80% 및 65-80%의 짝샘플에서 종양 미세환경의 변화(CD8+ 증가, IDO/PD-L1/Treg 감소)를 보여주는 전이적(translational) 데이터를 강조했다. IMUNON은 3상 OVATION 3의 등록 확대와 FDA의 선례에 맞춘 적응형, 이벤트 주도형 시험 설계를 설명했다.
재무 측면에서 Q3 순손실은 $3.4M (전년 동기 $4.8M)였고, 영업비용은 약 30% 감소했으며, 현금은 $5.3M로 회사는 이를 통해 2026년 1분기까지 운영을 자금 조달하며 선택적 자금 조달을 추구하고 있다고 밝혔다.
IMUNON (NASDAQ: IMNN) a publié les résultats du troisième trimestre 2025 et les progrès cliniques le 13 novembre 2025. L'entreprise a mis en évidence un bénéfice médian de survie globale (OS) de 13 mois observé avec IMNN-001 dans OVATION 2 et des données translationnelles montrant des basculements dans le microenvironnement tumoral (augmentation de CD8+, réduction de IDO/PD-L1/Treg) dans 50-80% et 65-80% des échantillons appariés. IMUNON a décrit l'extension de l'inscription au phase 3 OVATION 3 et une conception d'essai adaptative, dirigée par les événements, alignée sur les précédents de la FDA.
Sur le plan financier, la perte nette du T3 a été de $3.4M (contre $4.8M l'année précédente), les dépenses d'exploitation ont diminué d'environ 30%, et la trésorerie était de $5.3M, ce que l'entreprise indique financer les opérations jusqu'au premier trimestre 2026 tout en recherchant un financement sélectif.
IMUNON (NASDAQ: IMNN) meldete am 13. November 2025 die Ergebnisse des dritten Quartals 2025 und klinische Fortschritte. Das Unternehmen hob einen medianen 13-monatigen Gesamtüberlebensvorteil (OS) hervor, der bei IMNN-001 in OVATION 2 beobachtet wurde, sowie translationale Daten, die Veränderungen der Tumormikroumgebung zeigen (CD8+-Anstieg, reduzierte IDO/PD-L1/Treg) in 50-80% bzw. 65-80% der gepaarten Proben. IMUNON beschrieb eine erweiterte Rekrutierung in der Phase-3-Studie OVATION 3 und ein adaptives, ereignisgesteuertes Studiendesign, das mit FDA-Präzedenzfällen übereinstimmt.
Finanziell betrug der Nettoverlust im Q3 $3.4M (gegenüber $4.8M im Vorjahr), die Betriebsausgaben sanken um etwa 30%, und das Bargeld betrug $5.3M, was das Unternehmen sagt, die Operationen bis ins Q1 2026 zu finanzieren, während es eine selektive Finanzierung verfolgt.
IMUNON (NASDAQ: IMNN) أبلغت عن نتائج الربع الثالث 2025 وتقدمها السريري في 13 نوفمبر 2025. سلطت الشركة الضوء على فائدة بمتوسط 13 شهراً للبقاء على قيد الحياة الإجمالي(OS) الملحوظة مع IMNN-001 في OVATION 2 وبيانات ترانسلّية تُظهر تحولات في بيئة الورم الدقيقة (زيادة CD8+، تقليل IDO/PD-L1/Treg) في 50-80% و65-80% من العينات المرتبطة. وصفت IMUNON توسيع تسجيلها في المرحلة 3 OVATION 3 وتصميماً تجربة تكيفياً يعتمد على الأحداث متماشياً مع سابقي FDA.
مالياً، كانت الخسارة الصافية في الربع الثالث $3.4M (مقابل $4.8M في العام السابق)، وانخفضت المصروفات التشغيلية بنحو 30%، وزادت النقدية إلى $5.3M، وهو ما تقول الشركة إنه يمول العمليات حتى الربع الأول من 2026 أثناء سعيها للتمويل الانتقائي.
- Median 13-month OS benefit reported in OVATION 2
- R&D translational response in 50–80% of paired samples
- Operating expenses down 30% in Q3 2025 vs Q3 2024
- R&D expenses down ~42% in Q3 2025 vs Q3 2024
- Cash and cash equivalents of $5.3M with runway only into Q1 2026
- Net cash used in operations of $10.2M for nine months ended Sept 30, 2025
- Nine-month net loss of $10.3M through Sept 30, 2025
Insights
Phase 3 progress and supportive translational data contrast with a tight cash runway into
IMUNON advances its Phase 3 OVATION 3 program with strong translational signals and reported survival benefit signals from OVATION 2, which the company highlights as a mechanistic shift of the tumor microenvironment from “cold” to “hot.” The company presented consistent biomarker and tolerability data across multiple scientific meetings, described enrollment exceeding expectations, and noted a well‑precented, adaptive Phase 3 design aligned with the FDA.
Financially, operating discipline reduced operating expenses by
Key dependencies and risks are explicit: continued OVATION 3 enrollment and maintenance of the regulatory alignment described, availability of capital before
R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced ovarian cancer
Company to hold conference call today at 11:00 a.m. ET
LAWRENCEVILLE, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three-month and nine-month periods ended September 30, 2025, and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer.
“IMUNON is rapidly advancing a potential breakthrough for women with newly diagnosed advanced ovarian cancer—a disease with no meaningful frontline treatment progress in decades,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “Strong Phase 2 OVATION 2 survival data, reinforced by compelling interim results from our MRD study and a clear regulatory path in Phase 3, position IMNN-001 to deliver transformative impact.”
“Our clinical success has attracted increasing interest from the medical community and potential partners. As we advance the Phase 3 OVATION 3 Study, which is evaluating IMNN-001 in women with stage IIIC or IV ovarian cancer, we are committed to funding this pivotal trial strategically. We have taken steps to conserve cash and align our critical needs with available capital on hand, while securing the resources needed to advance this potentially transformative therapy with select financing opportunities,” Dr. Lindborg continued.
RECENT DEVELOPMENTS
IMNN-001 Immunotherapy
R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer – On November 10, 2025, the Company hosted an R&D Day, providing updates on new IMNN-001 data and discussing progress with the OVATION 3 Study and IMNN-001’s potential role in transforming the treatment landscape for women with advanced ovarian cancer. The event featured ovarian cancer thought leaders, principal investigators from the Company’s Phase 3 OVATION 3 Study and Phase 2 minimal residual disease (MRD) clinical trial (conducted in partnership with Break Through Cancer Foundation), and statistical experts.
R&D Day Featured Speakers and Program Highlights:
- Premal H. Thaker, M.D., Washington University School of Medicine, discussed the significant continuing unmet needs in ovarian cancer, a devastating disease where patient outcomes and frontline standard of care treatment have not changed for about 30 years, and the promise IMNN-001 brings to these patients and clinicians. She also highlighted the data from the Phase 2 OVATION 2 clinical trial, with results including:
- Broad impact observed with IMNN-001 treatment on important cancer-fighting cytokines, effectively turning the tumor microenvironment from “cold” to “hot” by activating both innate and adaptive immune systems, renewing the elusive promise of an immunotherapy for ovarian cancer.
- Data reinforcing the highly favorable benefit-risk and safety profile of IMMN 001.
- The remarkable median 13-month overall survival (OS) benefit observed with IMNN-001 plus standard of care (SoC) chemotherapy, an increase that is considered clinically meaningful compared to SoC alone.
- Amir Jazaeri, M.D., University of Texas MD Anderson Cancer Center, discussed safety, tolerability and translational insights from the Phase 2 MRD study of IMNN-001, including:
- Rationale for the trial and the importance of frontline therapy as the best opportunity to achieve a cure for ovarian cancer.
- New translational data that shows IMNN-001 preferentially being taken up by macrophages within the peritoneal fluid and tumor tissue, which then induces a robust response and tumor microenvironment remodeling.
- New data supporting the highly favorable benefit-risk and tolerability profile of IMNN-001.
- The positive tolerability profile of IMNN-001, including in combination with SoC chemotherapy plus bevacizumab, and in the maintenance setting.
- Giorgio Paulon, Ph.D., Berry Consultants, LLC, reviewed the Phase 2 and ongoing Phase 3 trial designs, and the strength of evidence for IMNN-001 from a statistical perspective. He highlighted the well-precedented nature of the Phase 3 design with the FDA, which leverages an innovative, adaptive, event-driven approach aligned with prior successful oncology trials that resulted in full approval by FDA based on an interim analysis of overall survival. This foundation, supported by conservative power assumptions drawn from Phase 2 data, strong simulation modeling and robust statistical properties, underpins the Phase 3 trial's high probability for success.
- Douglas V. Faller, M.D., Ph.D., IMUNON, shared new data further demonstrating IMNN-001 shifted the balance in favor of immune stimulation, remodeling the tumor microenvironment in favor of anti-tumor responses, which is established to be associated with better prognosis. He shared the rapid progress to-date on the Phase 3 trial of IMNN-001, including expansion to additional sites and enrollment exceeding the Company’s expectations, strong levels of support and interest from investigators and the scientific community, and key clinical and other milestones for the company moving forward.
The presentations from the R&D Day are available on the “Scientific Presentations” page of the IMUNON’s website at https://investors.imunon.com/scientific-presentations
IMUNON Presents Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting – On November 7, 2025, the Company presented translational data from the Phase 2 OVATION 2 clinical trial of IMNN-001 at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, held on November 5-9, 2025 in National Harbor, Maryland.
The new data from recently analyzed OVATION 2 samples demonstrated that IMNN-001 creates a “hot” anti-tumor microenvironment in epithelial ovarian cancer by (i) increasing the recruitment of anti-tumor CD8+, myeloid dendritic cells and M1 macrophages in patient tumors; and (ii) decreasing immunosuppressive markers (IDO, Treg, exhausted CD8, M2 macrophages). These results, including induction of favorable ratios of CD8+/Tregs and CD8+/CD4+ cells, which are both associated with improved patient outcomes, are consistent with the results of the previous OVATION 1 study and with the efficacy seen in the clinic in the OVATION 2 study. This biomarker research confirms local immune activation at the tumor site by IMNN-001.
The poster presentation is available on the “Scientific Presentations” page of the IMUNON’s website at https://investors.imunon.com/scientific-presentations
IMUNON Presents Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at the ESMO Congress and the IGCS 2025 Annual Global Meeting – On October 14, 2025, the Company announced that a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001 was presented at the European Society for Medical Oncology (ESMO) Congress 2025, held on October 17-21, 2025 in Berlin, Germany with an encore presentation following the 2025 Annual Global Meeting of the International Gynecologic Cancer Society (IGCS), held on November 5-7, 2025, in Cape Town, South Africa. The poster presentations are available on the “Scientific Presentations” page of the IMUNON’s website at https://investors.imunon.com/scientific-presentations
Positive Translational Data of IMNN-001 Presented at AACR Special Conference in Cancer Research Demonstrating 13 Month OS Extension via Tumor Micro-Environment Shift – On September 22, 2025, the Company presented positive translational data from the Phase 2 OVATION 2 Study of IMNN-001 at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Ovarian Cancer Research, held on September 19-21, 2025, in Denver, Colorado reinforcing the favorable safety profile and efficacy benefits of IMNN-001 observed in the clinic, including increases in key anti-cancer immune cytokines and modulation of relevant anti-tumor immune cell populations, such as CD8+ T cells and myeloid dendritic cells, in the tumor and tumor microenvironment in study participants post-treatment.
IMUNON reviewed translational data on the changes induced by the local administration of IL-12 and its downstream effectors in the tumor micro-environment (TME) from paired samples (pre- and post-treatment) from study participants. Results presented at the AACR Special Conference demonstrated:
- Positive shift in the local TME to favorable immune stimulatory T cell ratios in the majority of participants treated with IMNN-001, including favorable ratios of CD8+/T regulatory (Treg) cells, CD8+/IDO+ cells, and CD8+/CD4+ cells.
- TME shift in favor of decreased immunosuppression cells (IDO+, PDL1+, Treg, CD4+) and increased immunostimulatory cells (CD8+, CD8+ effector, myeloid dendritic cells) in the majority of participants post-treatment.
- IMNN-001 treatment creates a “hot” anti-TME by increasing the recruitment of anti-tumor CD8+ and myeloid dendritic cells in 50
-80% of the paired samples and decreasing immunosuppressive markers (IDO, PDL1, Treg cells) in 65-80% of the samples.
Results from the study continue to validate our TheraPlas® technology and the broad impact of IMNN-001 on important cancer-fighting cytokines, effectively turning the tumor microenvironment from “cold” to ‘hot’ by activating both innate and adaptive immune systems, with limited to no systemic toxicities. IMNN-001 has shown significant therapeutic potential in clinical trials thus far, and the robust survival benefits and favorable safety profile observed align with these translational findings, supporting the ongoing Phase 3 OVATION 3 trial.
The OVATION 2 Study poster presentation is available on the “Scientific Presentations” page of IMUNON’s website at https://investors.imunon.com/scientific-presentations.
PlaCCine® DNA Vaccine Technology
PlaCCine® DNA Technology Proof-of-Concept Data Presented in Platform Presentations at Leading Vaccine Conferences – On October 17, 2025, the Company announced that members of its leadership team will deliver oral presentations highlighting IMNN-101, its investigational DNA plasmid vaccine based on the Company’s proprietary PlaCCine® technology platform, including proof-of-concept clinical trial results at the following vaccine conferences:
- 5th Edition of International Vaccines Congress (IVC) Keynote Oral Presentation Title: A promising novel approach to DNA vaccines, on October 23 2025 and
- 10th International Conference on Vaccine Research and Development Oral Presentation Title: Development of a PlaCCine DNA Technology for Safe, Effective and Durable Vaccines, on November 6, 2025
These presentations described the unique design and composition of the PlaCCine technology and its differentiating features including a longer duration of antigen expression, safety, user compliance and storage stability at workable temperatures (up to one year at 4°C and one month at 37°C) in comparison to mRNA vaccines and other DNA vaccines requiring viruses or devices for delivery. The immunogenicity of the PlaCCine technology was demonstrated against various pathogens in multiple species and animal models. These presentations also demonstrated safety and immunogenicity of a PlaCCine vaccine targeting a SARS-CoV-2 spike variant in healthy human participants following intramuscular administration. Durable NAb responses to 6 months demonstrating vaccine immunogenicity following a single dose in previously vaccinated or infected individuals with the SARS-CoV-2 underscore the significance of the PlaCCine approach and support continued development in both naive populations using a prime and boost vaccination to determine optimal benefits and in other infectious diseases.
IMNN-101 has been shown to be safe and well tolerated, with no serious adverse effects reported. To accelerate the development and commercialization of the PlaCCine platform, IMUNON is actively seeking strategic partnerships with leading pharmaceutical and biotechnology companies. These collaborations aim to leverage PlaCCine’s unique advantages—enhanced durability, temperature stability, and scalable manufacturing—to address unmet needs in vaccines for infectious diseases and cancer, while securing non-dilutive funding to advance IMUNON’s broader oncology focused pipeline
THIRD QUARTER 2025 FINANCIAL RESULTS
Net loss for the third quarter of 2025 was
Research and development (R&D) expenses were
General and administrative (G&A) expenses were
Investment income from short-term investments was
As of September 30, 2025, cash and cash equivalents were
NINE MONTHS ENDED SEPTEMBER 30, 2025 FINANCIAL RESULTS
For the nine months ended September 30, 2025, the Company reported a net loss of
Net cash used for operating activities was
R&D expenses were
G&A expenses were
Investment income was
Please note: All share and per share amounts in this press release have been adjusted to reflect a 15-for-1 reverse split of our common stock (which we effected on July 25, 2025) and all per share amounts in this press release have been adjusted for the
Conference Call and Webcast
The Company is hosting a conference call to review third quarter 2025 financial results and provide a business update today, November 13, 2025, at 11:00 a.m. ET. To participate in the call, please dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON Third Quarter 2025 Financial Results Call. A live webcast of the call will also be available here.
The call will be archived for replay until November 27, 2025, and can be accessed at 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International Toll) using replay access code 4592282. An audio replay of the call will also be available here for 90 days.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). The first patient was dosed in the Company’s Phase 3 pivotal study in the third quarter of 2025. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), and include statements regarding our planned stock split. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, risks and uncertainties related to the reverse stock split having the desired effect, our ability to regain compliance with Nasdaq’s listing requirements, the potential de-listing of our shares on Nasdaq, risks and uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| CG Life | ICR Healthcare |
| Jenna Urban | Peter Vozzo |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
(Tables to Follow)
IMUNON, Inc.
Condensed Statements of Operations
(in thousands except per share amounts)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 1,899 | $ | 3,293 | $ | 5,291 | $ | 9,407 | ||||||||
| General and administrative | 1,577 | 1,668 | 5,098 | 5,579 | ||||||||||||
| Total operating expenses | 3,476 | 4,961 | 10,389 | 14,986 | ||||||||||||
| Loss from operations | (3,476 | ) | (4,961 | ) | (10,389 | ) | (14,986 | ) | ||||||||
| Other income: | ||||||||||||||||
| Investment income, net | 47 | 116 | 117 | 423 | ||||||||||||
| Total other income, net | 47 | 116 | 117 | 423 | ||||||||||||
| Net loss | $ | (3,429 | ) | $ | (4,845 | ) | $ | (10,272 | ) | $ | (14,563 | ) | ||||
| Net loss per common share | ||||||||||||||||
| Basic and diluted | $ | (1.16 | ) | $ | (3.76 | ) | $ | (5.53 | ) | $ | (14.13 | ) | ||||
| Weighted average shares outstanding | ||||||||||||||||
| Basic and diluted | 2,944 | 1,290 | 1,856 | 1,031 | ||||||||||||
IMUNON, Inc.
Selected Balance Sheet Information
(in thousands)
| September 30, 2025 | December 31, 2024 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 5.251 | $ | 5,873 | ||||
| Advances, deposits on clinical programs and other current assets | 2,007 | 2,136 | ||||||
| Total current assets | 7.258 | 8,009 | ||||||
| Property and equipment | 601 | 541 | ||||||
| Other assets: | ||||||||
| Operating lease right-of-use assets, net | 1,079 | 1,117 | ||||||
| Deposits and other assets | 50 | 50 | ||||||
| Total other assets | 1,129 | 1,167 | ||||||
| Total assets | $ | 8,988 | $ | 9,717 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued liabilities | $ | 3,804 | $ | 4,334 | ||||
| Operating lease liabilities - current portion | 394 | 452 | ||||||
| Total current liabilities | 4.198 | 4,786 | ||||||
| Operating lease liabilities - non-current portion | 708 | 687 | ||||||
| Total liabilities | 4,906 | 5,473 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock | 29 | 10 | ||||||
| Additional paid-in capital | 421,213 | 411,122 | ||||||
| Accumulated deficit | (417,075 | ) | (406,803 | ) | ||||
| Total stockholders’ equity before treasury stock | 4,167 | 4,329 | ||||||
| Treasury stock, at cost | (85 | ) | (85 | ) | ||||
| Total stockholders’ equity | 4,082 | 4,244 | ||||||
| Total liabilities and stockholders’ equity | $ | 8,988 | $ | 9,717 | ||||
# # #
FAQ
What clinical benefit did IMUNON (IMNN) report on November 13, 2025 for IMNN-001?
How far does IMUNON's cash position of $5.3M last for IMNN (as of Sept 30, 2025)?
What material trial is IMUNON advancing for IMNN-001 and what is its design?
How did IMUNON's expenses change in Q3 2025 compared to Q3 2024 (IMNN)?
What translational biomarker results did IMUNON present for IMNN-001 at AACR and SITC in 2025?
